Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Acute ST-segment elevation myocardial infarction (STEMI) is a significant cause of death and disability.
• Erythropoietin has shown promise in experimental models for reducing infarct size and improving left ventricular function post-myocardial infarction (MI).

Purpose of the Study:

• To assess the safety and efficacy of a single intravenous dose of epoetin alfa in patients experiencing STEMI.
• To determine if epoetin alfa administration impacts infarct size and left ventricular remodeling.

Main Methods:

• A prospective, randomized, double-blind, placebo-controlled trial (REVEAL) involving 222 STEMI patients undergoing percutaneous coronary intervention (PCI).
• Patients received either epoetin alfa (60,000 U) or placebo intravenously within 4 hours of reperfusion.
• Infarct size was measured using cardiac magnetic resonance (CMR) imaging at two time points: early post-intervention and 12 weeks later.

Main Results:

• No significant difference in infarct size was observed between the epoetin alfa and placebo groups at either early or late CMR assessments.
• A prespecified analysis indicated a larger infarct size in patients aged 70 years or older treated with epoetin alfa compared to placebo (P=.03).
• The incidence of composite adverse cardiovascular events (death, MI, stroke, stent thrombosis) was higher in the epoetin alfa group (4.0%) than in the placebo group (0%) (P=.04).

Conclusions:

• A single intravenous bolus of epoetin alfa within 4 hours of reperfusion did not reduce infarct size in STEMI patients.
• The treatment was associated with an increased risk of adverse cardiovascular events.
• Concerns were raised regarding a potential increase in infarct size among older patients treated with epoetin alfa.